Products for Research Use Only

Ursodeoxycholic acid

CAT: 0804-HY-13771-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13771-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ursodeoxycholic acid (Ursodeoxycholate) is a secondary bile acid issued from the transformation of (cheno) deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR) . Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection. Orally active[1][2][3][4].
CAS Number
128-13-2
Product Name Alternative
Ursodeoxycholate; Ursodiol; UDCA
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Angiotensin-converting Enzyme (ACE) ; Endogenous Metabolite; FXR; G protein-coupled Bile Acid Receptor 1
Type
Natural Products
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer; Infection; Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Ursodiol.html
Purity
99.94
Solubility
DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL
Smiles
C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
Molecular Formula
C24H40O4
Molecular Weight
392.57
Precautions
H302, H315, H319, H335
References & Citations
[1]Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46 (4) :1131-7.|[2]Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16 (1) :3-14.|[3]Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56 (4) :1300-10.|[4]Brevini T, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022 Dec 5.|[5]Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16 (2) :e0246161. Published 2021 Feb 18.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
Launched
Isoform
Human Endogenous Metabolite
Citation 01
Adv Sci (Weinh) . 2025 Feb 3:e2411719.|Adv Sci (Weinh) . 2025 Oct 27:e15370.|Aquaculture. 2024 Nov 15.|Cell Host Microbe. 2024 Feb 14;32 (2) :191-208.e9.|Cell Prolif. 2023 Nov;56 (11) :e13488.|Cells. 2022 Sep 21;11 (19) :2951.|Clin Neuropharmacol. 2022 Nov-Dec;45 (6) :168-174.|Free Radic Biol Med. 2020 May 20;152:821-837.|Int J Mol Sci. 2024 Jan 11;25 (2) :919.|J Transl Med. 2024 Dec 20;22 (1) :1124.|JCI Insight. 2025 Sep 23;10 (18) :e190716.|Lett Drug Des Discov. 2025 Nov 26.|Nat Commun. 2023 May 2;14 (1) :2523.|Nat Commun. 2025 Aug 16;16 (1) :7638.|Nature. 2025 Jul;643 (8070) :192-200.|Neurosci Lett. 2021 Jan 10;741:135493.|Phytomedicine. 2024 Sep:132:155886.|Phytomedicine. 2025 Apr:139:156495.|Res Sq. 2025 Nov 17.|Research Square Preprint. 2021 Aug.|Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870 (3) :167029.|Commun Biol. 2025 Jul 5;8 (1) :1009.